Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion

The Food and Drug Administration issued guidance for evaluating the cardiovascular risk of new diabetes mellitus drugs in 2008. Accumulating evidence from several completed trials conducted within this framework raises questions as to whether requiring safety outcome studies for all new diabetes mel...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Heart J Cardiovasc Pharmacother
Autors principals: Zannad, Faiez, Stough, Wendy Gattis, Lipicky, Raymond J., Tamargo, Juan, Bakris, George L., Borer, Jeffrey S., Alonso García, Maria de los Angeles, Hadjadj, Samy, Koenig, Wolfgang, Kupfer, Stuart, McCullough, Peter A., Mosenzon, Ofri, Pocock, Stuart, Scheen, André J., Sourij, Harald, Van der Schueren, Bart, Stahre, Christina, White, William B., Calvo, Gonzalo
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Reviews
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907355/
https://ncbi.nlm.nih.gov/pubmed/27418973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ehjcvp/pvw007
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars